September 13, 2024

 

Via EDGAR

 

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549-3720

Attention: Messrs. Dillon Hagius and Tim Buchmiller

 

	Re:	Kairos Pharma, Ltd.
		Withdrawal of Acceleration Request - Registration Statement on Form S-1 File No. 333-274805

 

Ladies and Gentlemen,

 

Kairos Pharma, Ltd. (the “Company”) hereby withdraws its request to accelerate the effectiveness of the above-referenced Registration Statement submitted by letter via EDGAR dated September 9, 2024. The Company will file a separate request to accelerate the effectiveness of the Registration Statement.

 

Please contact Megan J. Penick, Esq. of Dorsey & Whitney LLP, counsel for the Company, if you have any questions or concerns regarding this matter.

 

	Very truly yours,
	KAIROS PHARMA, LTD.
	By:	/s/ John S. Yu
		John S. Yu, M.D.
		Chief Executive Officer

 

cc:	Megan J. Penick, Esq.
	Dorsey & Whitney LLP